HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children (PROMOTE-PEDS)
Drug: LPV/r + 2 NRTIs
Drug: NVP or EFV + 2 NRTIs
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||A Randomized Open Label Trial of HIV Protease Inhibitors for the Prevention of Malaria in HIV-Infected Children|
- Incidence-density of malaria defined as the number of incident episodes of malaria per time at risk. [ Time Frame: Time from randomization to at least 24 months of follow up or until end of the study ] [ Designated as safety issue: No ]
- Incidence of any adverse events, defined as severity grade 2 or higher that are possibly, probably or definitely related to study drugs [ Time Frame: Time of randomization to at least 24 months or the end of the study ] [ Designated as safety issue: Yes ]
- To compare the virologic efficacy of LPV/r versus NNRTI-based ART in HIV-infected children, we will test for non-inferiority in the proportion of children who achieve HIV viral RNA suppression at 48 weeks [ Time Frame: Time of randomization to up to 24 months or end of study ] [ Designated as safety issue: No ]
- To compare immunologic efficacy of LPV/r versus NNRTI-based ART, we will test for non-inferiority in the change from baseline CD4 cell count and % at 2 time points; 48 and 96 weeks. [ Time Frame: Time of randomization to up to 24 months or end of study ] [ Designated as safety issue: No ]
- To assess the association between nutritional status and HIV-related outcomes, including ART levels [ Time Frame: Time of randomization to up to 24 months or end of study ] [ Designated as safety issue: No ]
|Study Start Date:||September 2009|
|Study Completion Date:||January 2013|
|Primary Completion Date:||January 2013 (Final data collection date for primary outcome measure)|
Experimental: Group 1
LPV/r + 2 NRTIs
Drug: LPV/r + 2 NRTIs
Lopinavir/ritonavir (LPV/r) +2 nucleoside reverse transcriptase inhibitor (NRTI)
The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin < 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.
Active Comparator: Group 2
NVP or EFV + 2 NRTIs
Drug: NVP or EFV + 2 NRTIs
Nevirapine (NVP) or Efavirenz (EFV) + 2 NRTI
NVP will be used for children < 3 years of age and EFV for children ≥3 years of age. The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin < 8 gm/dL, in which case it will be stavudine.
This is an open label, single site, randomized clinical trial comparing PI-based ART to NNRTI-based ART for the prevention of malaria in HIV-infected children. The two ART drug regimens that will be used include: Treatment arm 1. LPV/r + 2 NRTIs and Treatment arm 2. NVP or EFV + 2 NRTIs. The study is designed to test the hypothesis that children receiving a PI-based ART regimen will have lower the incidence of malaria compared to children receiving an NNRTI- based ART regimen. The primary study endpoint of the study is malaria incidence.
The study site will be the Tororo District Hospital campus situated in Eastern Uganda, an area of high malaria transmission. Using convenience sampling, 300 HIV-infected children identified from the Tororo community aged 2 months to <11 years either eligible for ART-initiation or already receiving a first line ART regimen with HIV RNA<400 copies/ml will be evaluated for enrollment.
Eligible children will be randomized at enrollment to receive either a PI- based or an NNRTI-based ART regimen. At enrollment, all study participants will receive a long lasting ITN as part of a basic care package including a safe water vessel and multivitamins and given TS chemoprophylaxis, as per current standard of care for HIV-infected children in Uganda. On the day of ART initiation, patients will be counseled about the importance of adherence to ART and possible ART related toxicities. After 2 weeks, patients will be seen to assess adherence and toxicity to study medications by interview and clinical examination. Apart from this visit at week 2, patients will be seen at 4 week intervals timed from ART-initiation. Assessment of adherence will also be done for TS prophylaxis, ITN use and ART. Assessment of adherence to ART will be done by self report of missed doses and pill counts.
Participants will receive all routine and acute medical care at a designated study clinic open 7 days a week from 8 a.m. to 5 p.m. Parents/guardians will be asked to bring their child to the study clinic for all medical care. If after hours, they will be instructed to bring them to Tororo District Hospital premises (where the study clinic is located) and request that the study physician on-call be contacted. They will be followed for at least 24 months and up to 3 years. They will be seen monthly for routine assessments with laboratory evaluations done at every 3 months. At these visits, the study protocol will be reinforced with discussion regarding the need to come to the study clinic promptly upon the onset of any illness and to avoid use of outside medications. Study participants will also be followed closely for adverse events potentially due to study drugs and for malaria and HIV treatment outcomes. During the follow-up period, all patients presenting to the clinic with a new episode of fever will undergo standard evaluation (history, physical examination) and Giemsa-stained blood smear for the diagnosis of malaria.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00978068
|IDRC - Tororo Research Clinic|
|Study Director:||Diane V Havlir, MD||University of California, San Francisco|
|Principal Investigator:||Moses R Kamya MBChB, MMed, MPH||Makerere University|
|Principal Investigator:||Grant Dorsey, MD, PhD||University of California, San Francisco|
|Principal Investigator:||Ted Ruel, MD||University of California, San Francisco|
|Principal Investigator:||Jane Achan, MBChB, MPed||Makerere University|